<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37727759</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Longitudinal clinical phenotyping of post COVID condition in Mexican adults recovering from severe COVID-19: a prospective cohort study.</ArticleTitle><Pagination><StartPage>1236702</StartPage><MedlinePgn>1236702</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1236702</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2023.1236702</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Few studies have evaluated the presence of Post COVID-19 conditions (PCC) in people from Latin America, a region that has been heavily afflicted by the COVID-19 pandemic. In this study, we describe the frequency, co-occurrence, predictors, and duration of 23 symptoms in a cohort of Mexican patients with PCC.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We prospectively enrolled and followed adult patients hospitalized for severe COVID-19 at a tertiary care centre in Mexico City. The incidence of PCC symptoms was determined using questionnaires. Unsupervised clustering of PCC symptom co-occurrence and Kaplan-Meier analyses of symptom persistence were performed. The effect of baseline clinical characteristics was evaluated using Cox regression models and reported with hazard ratios (HR).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">We found that amongst 192 patients with PCC, respiratory problems were the most prevalent and commonly co-occurred with functional activity impairment. 56% had &#x2265;5 persistent symptoms. Symptom persistence probability at 360&#x2009;days 0.78. Prior SARS-CoV-2 vaccination and infection during the Delta variant wave were associated with a shorter duration of PCC. Male sex was associated with a shorter duration of functional activity impairment and respiratory symptoms. Hypertension and diabetes were associated with a longer duration of functional impairment. Previous vaccination accelerated PCC recovery.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">In our cohort, PCC symptoms were frequent (particularly respiratory and neurocognitive ones) and persistent. Importantly, prior SARS-CoV-2 vaccination resulted in a shorter duration of PCC.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 N&#xfa;&#xf1;ez, Gillard, Fragoso-Saavedra, Feyaerts, Islas-Weinstein, Gallegos-Guzm&#xe1;n, Valente-Garc&#xed;a, Meyerowitz, Kelly, Chen, Ganio, Benkendorff, Flores-Gouyonnet, Dammann-Beltr&#xe1;n, Heredia-Gonz&#xe1;lez, Rangel-Guti&#xe9;rrez, Blish, Nadeau, Nolan, Crisp&#xed;n, McIlwain, Gaudilli&#xe8;re and Vald&#xe9;s-Ferrer.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>N&#xfa;&#xf1;ez</LastName><ForeName>Isaac</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Medical Education, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Postrgraduate Studies, Faculty of Medicine, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gillard</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Section Pediatric Infectious Diseases, Laboratory of Medical Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Molecular and Biomolecular Informatics, Radboud University Medical Center, Nijmegen, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fragoso-Saavedra</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medical Education, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Postrgraduate Studies, Faculty of Medicine, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Combined Study Plan in Medicine, Faculty of Medicine, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feyaerts</LastName><ForeName>Dorien</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Islas-Weinstein</LastName><ForeName>Le&#xf3;n</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology &amp; Psychiatry, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallegos-Guzm&#xe1;n</LastName><ForeName>Angel A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Neurology &amp; Psychiatry, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valente-Garc&#xed;a</LastName><ForeName>Uriel</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Neurology &amp; Psychiatry, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyerowitz</LastName><ForeName>Justin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>J Daniel</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, UCSF, San Francisco, CA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Global Health Sciences, UCSF, San Francisco, CA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>F.IProctor Foundation, UCSF, San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Han</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganio</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benkendorff</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flores-Gouyonnet</LastName><ForeName>Jaime</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology &amp; Psychiatry, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dammann-Beltr&#xe1;n</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology &amp; Psychiatry, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heredia-Gonz&#xe1;lez</LastName><ForeName>Jos&#xe9; Francisco</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Combined Study Plan in Medicine, Faculty of Medicine, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rangel-Guti&#xe9;rrez</LastName><ForeName>Gabriela A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Combined Study Plan in Medicine, Faculty of Medicine, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blish</LastName><ForeName>Catherine A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chan Zuckerberg Biohub, San Francisco, CA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Stanford University, Stanford, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nadeau</LastName><ForeName>Kari C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Stanford, CA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford University, Stanford, CA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Immunity, Transplantation, and Infectious Diseases, Stanford University, Stanford, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nolan</LastName><ForeName>Garry</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pathology, Stanford University School of Medicine, Stanford, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crisp&#xed;n</LastName><ForeName>Jose C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>School of Medicine and Health Sciencies, Tecnologico de Monterrey, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology and Rheumatology, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McIlwain</LastName><ForeName>David R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaudilli&#xe8;re</LastName><ForeName>Brice</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vald&#xe9;s-Ferrer</LastName><ForeName>Sergio I</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>Department of Neurology &amp; Psychiatry, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Biomedical Science, Feinstein Institutes for Medical Research, New York, NY, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Mexico</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">persistent COVID</Keyword><Keyword MajorTopicYN="N">post-COVID-19 conditions</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>20</Day><Hour>3</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37727759</ArticleId><ArticleId IdType="pmc">PMC10505811</ArticleId><ArticleId IdType="doi">10.3389/fmed.2023.1236702</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO coronavirus (COVID-19) dashboard. Available at: https://COVID19.who.int/ (Accessed July 28, 2023)</Citation></Reference><Reference><Citation>Secretar&#xed;a De Salud G De M . Reporte de vigilancia gen&#xf3;mica del virus SARS-CoV-2 en M&#xe9;xico Distribuci&#xf3;n nacional y estatal de variantes al 04 de abril de 2022. Available at: https://coronavirus.gob.mx/wp-content/uploads/2022/04/2022.04.04-Varientes-COVID-MX.pdf (Accessed July 28, 2023)</Citation></Reference><Reference><Citation>Bhimraj A, Morgan RL, Hirsch Shumaker A, et al. . Infectious Diseases Society of America guidelines on the treatment and Management of Patients with COVID-19. Available at: www.idsociety.org/COVID19guidelines. (Accessed May 28, 2023)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7197612</ArticleId><ArticleId IdType="pubmed">32338708</ArticleId></ArticleIdList></Reference><Reference><Citation>Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. (2021) 21:626&#x2013;36. doi: 10.1038/s41577-021-00592-1, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00592-1</ArticleId><ArticleId IdType="pmc">PMC8351583</ArticleId><ArticleId IdType="pubmed">34373623</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. (2020) 324:603&#x2013;5. doi: 10.1001/jama.2020.12603, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C, Pellicer-Valero OJ, Navarro-Pardo E, Palacios-Ce&#xf1;a D, Florencio LL, Guijarro C, et al. . Symptoms experienced at the acute phase of SARS-CoV-2 infection as risk factor of long-term post-COVID symptoms: the LONG-COVID-EXP-CM multicenter study. Int J Inf Dis. (2022) 116:241&#x2013;4. doi: 10.1016/j.ijid.2022.01.007, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.01.007</ArticleId><ArticleId IdType="pmc">PMC8743274</ArticleId><ArticleId IdType="pubmed">35017102</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. . Attributes and predictors of long COVID. Nat Med. (2021) 27:626&#x2013;31. doi: 10.1038/s41591-021-01292-y, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. . Post-acute COVID-19 syndrome. Nat Med. (2021) 27:601&#x2013;15. doi: 10.1038/s41591-021-01283-z, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Coronavirus disease (COVID-19): post COVID-19 condition. Available at: https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(COVID-19)-post-COVID-19-condition. (Accessed March 28, 2023)</Citation></Reference><Reference><Citation>Yelin D, Moschopoulos CD, Margalit I, Gkrania-Klotsas E, Landi F, Stahl JP, et al. . ESCMID rapid guidelines for assessment and management of long COVID. Clin Microbiol Inf. (2022) 28:955&#x2013;72. doi: 10.1016/j.cmi.2022.02.018, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.02.018</ArticleId><ArticleId IdType="pmc">PMC8849856</ArticleId><ArticleId IdType="pubmed">35182760</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Grimshaw M, Sankowski R, Vald&#xe9;s-Ferrer SI. Neurocognitive and psychiatric post-coronavirus disease 2019 conditions: pathogenic insights of brain dysfunction following severe acute respiratory syndrome coronavirus 2 infection. Curr Opin Neurol. (2022) 35:375&#x2013;83. doi: 10.1097/WCO.0000000000001046</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000001046</ArticleId><ArticleId IdType="pubmed">35283463</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz J. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. (2022) 22:e102&#x2013;7. doi: 10.1016/S1473-3099(21)00703-9, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>See&#xdf;le J, Waterboer T, Hippchen T, Simon J, Kirchner M, Lim A, et al. . Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID-19): a prospective cohort study. Clin Inf Dis. (2022) 74:1191&#x2013;8. doi: 10.1093/cid/ciab611, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab611</ArticleId><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia X, Cao S, Lee AS, Manohar M, Sindher SB, Ahuja N, et al. . Anti-nucleocapsid antibody levels and pulmonary comorbid conditions are linked to post-COVID-19 syndrome. JCI Insight. (2022) 7:e156713. doi: 10.1172/jci.insight.156713, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.156713</ArticleId><ArticleId IdType="pmc">PMC9310538</ArticleId><ArticleId IdType="pubmed">35801588</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. . Multiple early factors anticipate post-acute COVID-19 sequelae. Cells. (2022) 185:881&#x2013;895.e20. doi: 10.1016/j.cell.2022.01.014, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19. JAMA Netw Open. (2021) 4:e2111417. doi: 10.1001/jamanetworkopen.2021.11417, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.11417</ArticleId><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Yao Q, Gu X, Wang Q, Ren L, Wang Y, et al. . 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. (2021) 398:747&#x2013;58. doi: 10.1016/S0140-6736(21)01755-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01755-4</ArticleId><ArticleId IdType="pmc">PMC8389999</ArticleId><ArticleId IdType="pubmed">34454673</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans RA, Leavy OC, Richardson M, Elneima O, McAuley HJC, Shikotra A, et al. . Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med. (2022) 10:761&#x2013;75. doi: 10.1016/S2213-2600(22)00127-8, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00127-8</ArticleId><ArticleId IdType="pmc">PMC9034855</ArticleId><ArticleId IdType="pubmed">35472304</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakhamuri SM, Jankie S, Pinto Pereira LM. Calling on Latin America and the Caribbean countries to recognise the disability from long COVID. Lancet Reg Health Am. (2022) 15:100362. doi: 10.1016/j.lana.2022.100362, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2022.100362</ArticleId><ArticleId IdType="pmc">PMC9412073</ArticleId><ArticleId IdType="pubmed">36043156</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xfa;&#xf1;ez I, Soto-Mota A. Impact of healthcare strain on access to mechanical ventilation and mortality of hospitalized COVID-19 patients: a retrospective cohort study. Trans R Soc Trop Med Hyg. (2023) 117:383&#x2013;90. doi: 10.1093/trstmh/trac123, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/trstmh/trac123</ArticleId><ArticleId IdType="pubmed">36563101</ArticleId></ArticleIdList></Reference><Reference><Citation>Horby P, Lim WS, Emberson JR, et al. . Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. (2021) 384:693&#x2013;704. doi: 10.1056/NEJMoa2021436, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. . Compassionate use of Remdesivir for patients with severe COVID-19. N Engl J Med. (2020) 382:2327&#x2013;36. doi: 10.1056/NEJMoa2007016, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007016</ArticleId><ArticleId IdType="pmc">PMC7169476</ArticleId><ArticleId IdType="pubmed">32275812</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. . Baricitinib plus Remdesivir for hospitalized adults with COVID-19. N Engl J Med. (2021) 384:795&#x2013;807. doi: 10.1056/NEJMoa2031994, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2031994</ArticleId><ArticleId IdType="pmc">PMC7745180</ArticleId><ArticleId IdType="pubmed">33306283</ArticleId></ArticleIdList></Reference><Reference><Citation>Fragoso-Saavedra S, Iruegas-Nunez DA, Quintero-Villegas A, Garc&#xed;a-Gonz&#xe1;lez HB, Nu&#xf1;ez I, Carbajal-Morelos SL, et al. . A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine in severe COVID-19 (PISCO) trial protocol. BMC Infect Dis. (2020) 20:765. doi: 10.1186/s12879-020-05485-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-020-05485-7</ArticleId><ArticleId IdType="pmc">PMC7563903</ArticleId><ArticleId IdType="pubmed">33066761</ArticleId></ArticleIdList></Reference><Reference><Citation>Fragoso-Saavedra S, N&#xfa;&#xf1;ez I, Audelo-Cruz BM, Arias-Mart&#xed;nez S, Manzur-Sandoval D, Quintero-Villegas A, et al. . Pyridostigmine reduces mortality of patients with severe SARS-CoV-2 infection: a phase 2/3 randomized controlled trial. Mol Med. (2022) 28:131. doi: 10.1186/s10020-022-00553-x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10020-022-00553-x</ArticleId><ArticleId IdType="pmc">PMC9644007</ArticleId><ArticleId IdType="pubmed">36348276</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedro-Tanda A, G&#xf3;mez-Romero L, Alcaraz N, de Anda-Jauregui G, Pe&#xf1;aloza F, Moreno B, et al. . The evolutionary landscape of SARS-CoV-2 variant B.1.1.519 and its clinical impact in Mexico City. Viruses. (2021) 13:2182. doi: 10.3390/v1311218226, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v1311218226</ArticleId><ArticleId IdType="pmc">PMC8617872</ArticleId><ArticleId IdType="pubmed">34834987</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. . The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. (2020) 172:577&#x2013;82. doi: 10.7326/M20-0504, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-0504</ArticleId><ArticleId IdType="pmc">PMC7081172</ArticleId><ArticleId IdType="pubmed">32150748</ArticleId></ArticleIdList></Reference><Reference><Citation>Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. (1994) 81:515&#x2013;26. doi: 10.1093/biomet/81.3.515</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/81.3.515</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogundimu EO, Altman DG, Collins GS. Adequate sample size for developing prediction models is not simply related to events per variable. J Clin Epidemiol. (2016) 76:175&#x2013;82. doi: 10.1016/j.jclinepi.2016.02.031, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2016.02.031</ArticleId><ArticleId IdType="pmc">PMC5045274</ArticleId><ArticleId IdType="pubmed">26964707</ArticleId></ArticleIdList></Reference><Reference><Citation>Therneau TM, Lumley T. A Package for survival analysis in R. R package version 3.5-3. (2023). Available at: https://cran.r-project.org/web/packages/survival/index.html. (Accessed February 23, 2023)</Citation></Reference><Reference><Citation>Wickham H, Averick M, Bryan J, Chang W, McGowan L, Fran&#xe7;ois R, et al. . Welcome to the Tidyverse. J Open Source Softw. (2019) 4:1686. doi: 10.21105/joss.01686</Citation><ArticleIdList><ArticleId IdType="doi">10.21105/joss.01686</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickham H., ggplot2: elegant graphics for data analysis. Springer-Verlag New York, (2016), Available at: https://ggplot2.tidyverse.org. (Accessed February 23, 2023)</Citation></Reference><Reference><Citation>Bello-Chavolla OY, Ferm&#xed;n-Mart&#xed;nez CA, Fern&#xe1;ndez-Chirino L, et al. . Nationally representative prevalence and determinants of post-acute sequelae of SARS-CoV-2 infection (long COVID) amongst Mexican adults in 2022. Medrxiv. (2023) Preprint, not peer reviewed</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10847769</ArticleId><ArticleId IdType="pubmed">38327277</ArticleId></ArticleIdList></Reference><Reference><Citation>Rom&#xe1;n-Montes CM, Flores-Soto Y, Guaracha-Basa&#xf1;ez GA, et al. . Post-COVID-19 syndrome and quality of life impairment in severe COVID-19 Mexican patients. Front Public Health. (2023) 11:1155951. doi: 10.3389/fpubh.2023.1155951, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2023.1155951</ArticleId><ArticleId IdType="pmc">PMC10225709</ArticleId><ArticleId IdType="pubmed">37255755</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Sillett R, Zhu L, Mendel J, Camplisson I, Dercon Q, et al. . Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1&#x2008;284&#x2008;437 patients. Lancet Psychiat. (2022) 9:815&#x2013;27. doi: 10.1016/S2215-0366(22)00260-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(22)00260-7</ArticleId><ArticleId IdType="pmc">PMC9385200</ArticleId><ArticleId IdType="pubmed">35987197</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xfa;&#xf1;ez I. Home or hospital? An observational study of what affects the place of death of people with COVID-19. Trans R Soc Trop Med Hyg. (2023). In press). doi: 10.1093/trstmh/trad025</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/trstmh/trad025</ArticleId><ArticleId IdType="pubmed">37099410</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolini E, Levi R, Sarti R, Pozzi C, Mollura M, Mantovani A, et al. . Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in health care workers. JAMA. (2022) 328:676&#x2013;8. doi: 10.1001/jama.2022.11691, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.11691</ArticleId><ArticleId IdType="pmc">PMC9250078</ArticleId><ArticleId IdType="pubmed">35796131</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Bermingham C, Pouwels KB, Glickman M, Nafilyan V, Zaccardi F, et al. . Trajectory of long COVID symptoms after COVID-19 vaccination: community based cohort study. BMJ. (2022) 377:e069676. doi: 10.1136/bmj-2021-069676, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-069676</ArticleId><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. (2022) 28:1461&#x2013;7. doi: 10.1038/s41591-022-01840-0, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Carpio-Orantes L. Etiopathogenic theories about long COVID. World J Virol. (2023) 12:204&#x2013;8. doi: 10.5501/wjv.v12.i3.204, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.5501/wjv.v12.i3.204</ArticleId><ArticleId IdType="pmc">PMC10311581</ArticleId><ArticleId IdType="pubmed">37396704</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodin P, Casari G, Townsend L, O&#x2019;Farrelly C, Tancevski I, L&#xf6;ffler-Ragg J, et al. . Studying severe long COVID to understand post-infectious disorders beyond COVID-19. Nat Med. (2022) 28:879&#x2013;82. doi: 10.1038/s41591-022-01766-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01766-7</ArticleId><ArticleId IdType="pubmed">35383311</ArticleId></ArticleIdList></Reference><Reference><Citation>Zali A, Khodadoost M, Gholamzadeh S, Janbazi S, Piri H, Taraghikhah N, et al. . Mortality among hospitalized COVID-19 patients during surges of SARS-CoV-2 alpha (B.1.1.7) and delta (B.1.617.2) variants. Sci Rep. (2022) 12:18918. doi: 10.1038/s41598-022-23312-8, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-23312-8</ArticleId><ArticleId IdType="pmc">PMC9640720</ArticleId><ArticleId IdType="pubmed">36344540</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai D, Khan AR, Soneja M, Mittal A, Naik S, Kodan P, et al. . Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study. Lancet Infect Dis. (2022) 22:349&#x2013;56. doi: 10.1016/S1473-3099(21)00674-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00674-5</ArticleId><ArticleId IdType="pmc">PMC8610201</ArticleId><ArticleId IdType="pubmed">34826383</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiruvengadam R, Binayke A, Awasthi A. SARS-CoV-2 delta variant: a persistent threat to the effectiveness of vaccines. Lancet Infect Dis. (2022) 22:301&#x2013;2. doi: 10.1016/S1473-3099(21)00697-6, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00697-6</ArticleId><ArticleId IdType="pmc">PMC8610239</ArticleId><ArticleId IdType="pubmed">34826382</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi B, Sudry T, Flaks-Manov N, Yehezkelli Y, Kalkstein N, Akiva P, et al. . Long COVID outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ. (2023) 380:e072529. doi: 10.1136/bmj-2022-072529, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-072529</ArticleId><ArticleId IdType="pmc">PMC9832503</ArticleId><ArticleId IdType="pubmed">36631153</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. (2022) 399:2263&#x2013;4. doi: 10.1016/S0140-6736(22)00941-2, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00941-2</ArticleId><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez Padilla R, Torre-Bouscoulet L, Mui&#xf1;o A, et al. . Prevalence of oxygen desaturation and use of oxygen at home in adults at sea level and at moderate altitude. Eur Resp J. (2006) 27:594&#x2013;9. doi: 10.1183/09031936.06.00075005, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.06.00075005</ArticleId><ArticleId IdType="pubmed">16507861</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>